Enveric Biosciences Inc (SLZA.MU)
| Previous close | 0.7150 |
| Open | 0.7080 |
| Bid | 0.7120 x N/A |
| Ask | 0.7420 x N/A |
| Day's range | 0.7080 - 0.7080 |
| 52-week range | 0.7080 - 4.2250 |
| Volume | |
| Avg. volume | 21 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireEnveric Biosciences to Participate in BIO International Convention 2024
CAMBRIDGE, Mass., May 30, 2024--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company will participate in the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024.
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Ayr Wellness reported solid first quarter results. Cresco Labs reported stagnant sales but an optimistic outlook for 2024. Tilray announced a $250 million equity offering to fund U.S. asset acquisitions amid legalization optimism. Flora Growth is strategizing on cannabis reform to its reverse financial trend. Key Takeaways; Psychedelic Sector Enveric Biosciences […]
Business WireEnveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
CAMBRIDGE, Mass., May 15, 2024--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter of 2024 ended March 31, 2024.
